Jetbio
Jetbio offers 3D bioprinting systems that utilize patented Reactive Jet Impingement (ReJI) technology to print high cell density, human-like tissue models for drug discovery and regenerative medicine.
- CEO / Founder
- Dennis Camilleri
- Team Size
- 11-50
- Stage
- Active
- Total Funding
- $825K
- Latest Round
- Seed
- Key Investors
- Angel Investors
Technology & Products
Key Products
Reactive Jet Impingement (ReJI) 3D Bioprinter and Bioinks
Technological Advantage
Provides rapid, high-density bioprinting that reduces drug development time and costs while delivering more accurate, biomimetic tissue models.
Differentiation
Value Proposition
Delivers fast, accurate, and flexible bioprinting that mimics human tissue architecture, accelerating drug discovery and advancing regenerative medicine applications.
How They Differentiate
Utilizes novel ReJI technology to achieve significantly higher cell density and faster printing speeds, enabling more precise human-like tissue models.
Market & Competition
Target Customers
Pharmaceutical companies, research institutions, and healthcare organizations
Industry Verticals
["Pharmaceutical","Biotechnology","Healthcare","Regenerative Medicine"]
Competitors
Organovo, CELLINK
Growth & Milestones
Growth Metrics
Planned installations at end-user sites and growing adoption via academic and industry collaborations
Major Milestones
["Established as a spin-out from Newcastle University","Granted patents in Europe and the USA","Participation in the EC-funded REBORN project","Showcased technology to public health leaders including Professor Sir Chris Whitty"]
Notable Customers
Academic institutions; Industry partners; Versus Arthritis